ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

TERN Terns Pharmaceuticals Inc

4.25
-0.21 (-4.71%)
11 Feb 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Terns Pharmaceuticals Inc NASDAQ:TERN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.21 -4.71% 4.25 4.23 4.32 4.44 4.23 4.38 1,266,225 22:19:36

Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

05/02/2025 9:05pm

GlobeNewswire Inc.


Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart


From Jan 2025 to Feb 2025

Click Here for more Terns Pharmaceuticals Charts.

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025 at 4:00 p.m. ET.

A live webcast of the event will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website for at least 30 days following the presentations.

About Terns PharmaceuticalsTerns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: www.ternspharma.com.

Contacts for Terns

InvestorsJustin Ng investors@ternspharma.com

MediaJenna UrbanBerry & Company Public Relationsmedia@ternspharma.com

1 Year Terns Pharmaceuticals Chart

1 Year Terns Pharmaceuticals Chart

1 Month Terns Pharmaceuticals Chart

1 Month Terns Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock